SE-associated transcriptional programs have been implicated in aggressive tumor phenotypes, metastasis, and resistance to anticancer therapies, and BRD4 is frequently overexpressed in HNSCC, correlating with poor clinical outcomes [33]. Here, BRD4 is linked to neoplasm.